We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

According to Statifacts, the global clinical trials market size is calculated at USD 126.30 billion in 2025 and is expected to reach around USD 186.09 billion by 2034, growing at a CAGR of 4.4% from ...

Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly ...

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 18 unusual trades. Delving into the details, we found 33 ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in patients aged one to 11 years. The phase 3 FRONTIER3 trial initially evaluated a ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...

Novo Nordisk A/S today announced 2024 earnings ... for a margin of ~44% — high even by “Big Pharma” standards, and diluted earnings per share were reported as ~$3.2, which equates to ...

Novo Nordisk reported $40.5 billion in sales for ... in a race with rival drugmakers to deliver GLP-1s in pill form. The pharmaceutical giant and maker of Ozempic and Wegovy reported better ...